Press Releases

August 30, 2019

SpringWorks Therapeutics Appoints Alan Fuhrman to its Board of Directors

August 29, 2019

SpringWorks Therapeutics Receives Breakthrough Therapy Designation for Nirogacestat for the Treatment of Adult Patients with Progressive, Unresectable, Recurrent or Refractory Desmoid Tumors

August 15, 2019

SpringWorks Therapeutics Announces Appointment of Frank Perier as Chief Financial Officer

July 30, 2019

European Commission Grants Orphan Drug Designation for SpringWorks Therapeutics’ MEK Inhibitor, Mirdametinib, for the Treatment of Neurofibromatosis Type 1

June 27, 2019

SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma

June 18, 2019

BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

June 3, 2019

SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1

May 20, 2019

SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid Tumors

May 6, 2019

SpringWorks Therapeutics Announces Initiation of Phase 1b Clinical Trial of MEK Inhibitor PD-0325901 in Combination with BeiGene’s RAF Dimer Inhibitor Lifirafenib in Advanced or Refractory Solid Tumors

April 1, 2019

SpringWorks Therapeutics Completes $125 Million Series B Financing

March 4, 2019

SpringWorks Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference

December 20, 2018

SpringWorks Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

November 7, 2018

SpringWorks Therapeutics Receives FDA Fast Track Designation for Nirogacestat for the Treatment of Adult Patients with Desmoid Tumors

November 5, 2018

SpringWorks Therapeutics Receives FDA Orphan Drug Designation for MEK Inhibitor (PD-0325901) for the Treatment of Neurofibromatosis Type 1

September 6, 2018

BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors

September 5, 2018

SpringWorks Therapeutics Announces Appointment of Saqib Islam as Chief Executive Officer

March 5, 2018

SpringWorks Therapeutics to Present at Cowen and Company’s 38th Annual Health Care Conference

January 4, 2018

SpringWorks Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

September 25, 2017

SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs